

#12
JB
12/2/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Arlington, VA 22202, on the date appearing below.

ELI LILLY AND COMPANY

By _____

Date _____

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Ronald N. Hermeling et al.)	
Serial No.	: 09/997,792)	
Filed	: November 30, 2001)	Group Art Unit:
)	1653
For	: Glucagon-Like Peptide-1)	Examiner
	Crystals)	J. Russel
Docket No.	: X-10242A)	

SUPPLEMENTAL STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. 1.821(f) (SEQUENCE LISTING)

Assistant Commissioner for Patents
Arlington, VA 22202

Sir:

I hereby affirm that the content of the paper and computer readable copies of the Sequence Listing, submitted on September 30, 2002, are in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same and represent no new matter.

Respectfully submitted,



Mark J. Stewart
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

November 19, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Arlington, VA 22202, on the date appearing below.

ELI LILLY AND COMPANY

By YB Blodder

Date 9-30-02

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Ronald N. Hermeling et al.)	
)	
Serial No.	: 09/997,792)	
)	Group Art Unit:
Filed	: November 30, 2001)	1653
)	
For	: Glucagon-Like Peptide-1)	Examiner
	Crystals)	J. Russel
)	
Docket No.	: X-10242A)	

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. 1.821(f) (SEQUENCE LISTING)

Assistant Commissioner for Patents
Arlington, VA 22202
Sir:

I hereby affirm that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

Respectfully submitted,



Mark J. Stewart
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

September 30, 2002

Lilly

Fax

Eli Lilly and Company
Lilly Corporate Centre
Indianapolis, Indiana 46265
U.S.A.

Date: November 19, 2002

To: Jeff Russell
Company:
Fax: 703-746-5175
Phone:

From: Mark Stewart
Fax: 317-433-6679
Phone: 317-276-0280
Total Pages: 3

Privileged and Confidential Communication

Subject: Supplemental Sequence Statement for X-10242A

Hi Jeff:

Per our discussion this morning, I am forwarding a supplemental statement for X-10242A.

Thanks,
Mark